Efficacy and Tolerability of Preservative-Free Eye Drops Containing a Fixed Combination of Dorzolamide and Timolol in Glaucoma Patients
Authors:
- 1 December 2010
- journal article
- research article
- Published by SAGE Publications in Journal of Ocular Pharmacology and Therapeutics
- Vol. 26 (6) , 597-603
Abstract
Purpose: To evaluate the efficacy and tolerability of preservative-free eye drops (dorzolamide/timolol) in routine management of preservative-sensitive glaucoma patients. Methods: Data from 2,298 glaucoma patients requiring intraocular pressure (IOP) reduction and suffering from intolerance to benzalkonium chloride or active agents of previously used eye drops were valid for baseline and safety analysis in this prospective, open, noncomparative, multicenter, noninterventional study. Patients were treated with preservative-free dorzolamide/timolol eye drops for 12 weeks. Main efficacy endpoint was IOP reduction after 12 weeks of treatment. Two thousand forty-nine patients were considered for efficacy analysis. Tolerability was assessed by evaluating adverse drug reactions. Results: Mean baseline IOP was 20.8 mmHg. Baseline IOP was reduced to 16.7 mmHg after 12 weeks of treatment corresponding to a mean absolute (percent) change of −4.1 mmHg (−17.3%). The proportion of patients with IOP ≤21 mmHg increased from 59.9% at baseline to 94.6% after 12 weeks. The most frequently reported ocular adverse drug reactions were burning eyes (2.4%) and hyperemia (0.9%). Local tolerability improved in 79.3% of patients compared to their previous glaucoma therapy. Conclusions: This observational study confirms the IOP lowering effect of preservative-free eye drops containing the fixed combination of dorzolamide/timolol in a large patient's population. The drug was well tolerated and improved the local tolerability in the vast majority of patients.Keywords
This publication has 20 references indexed in Scilit:
- Cytotoxicity of ophthalmic solutions with and without preservatives to human corneal endothelial cells, epithelial cells and conjunctival epithelial cellsClinical & Experimental Ophthalmology, 2008
- Corneal and Conjunctival Changes Caused by Commonly Used Glaucoma MedicationsCornea, 2004
- Ocular surface inflammatory changes induced by topical antiglaucoma drugsOphthalmology, 1999
- Short term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteersBritish Journal of Ophthalmology, 1998
- To preserve or not to preserve, is that the question?British Journal of Ophthalmology, 1996
- Effect of timolol with and without preservative on the basal tear turnover in glaucoma.British Journal of Ophthalmology, 1995
- The effect of preservatives and antiglaucomatous medication on the histopathology of the conjunctivaGraefe's Archive for Clinical and Experimental Ophthalmology, 1994
- Conjunctival Impression Cytology in Patients With Glaucoma Using Long-term Topical MedicationAmerican Journal of Ophthalmology, 1991
- Adverse external ocular effects of topical ophthalmic medicationsSurvey of Ophthalmology, 1979
- Cytotoxicity of Ophthalmic PreservativesAmerican Journal of Ophthalmology, 1974